Navigation Links
ERA-EDTA Congress 2011: Late Breaking Clinical Trials II
Date:6/25/2011

PRAGUE, June 25, 2011 /PRNewswire/ --


 

The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatinleads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached the end point "end stage renal disease", but the difference was not significant [p = 0.41].

No improvement in cardiovascular outcome due to optimised treatment quality

Cardiovascular comorbidity in CKD patients is dramatically high. The MASTERPLAN study [abstract no. 2511] aimed to evaluate whether strict implementation of all the current treatment guidelines leads to a better cardiovascular outcome in CKD patients. The primary endpoint was a composite of myocardial infarction, stroke and cardiovascular death. Despite intensified therapy and better lab values it was not possible to significantly improve cardiovascular outcome in the intervention group.

Benefits of tacrolimus therapy with prolonged release in de novo kidney transplant patients

Various immunosuppressive drugs are available, one of these being tacrolimus (Tac). There are tacrolimus products that release their active substance immediately (Tac BID) and others that release it in a prolonged manner (Tac QD). The open-label OSAKA study [abstract no. 2505] compared these two drug forms in various doses. Tac QD led to the achievement of target blood level in more patients within the first few days after transplantation than Tac BID in an identical dose.

Which SHPT therapy should be used?

In the randomised phase IV IMPACT study [abstract no. 2519] 272 hemodialyis patients with seconday hyperparathyreoidism received either paricalcitol or cinacalcet plus low-dose vitamin D. This interim analysis showed that in the paricalcitol group 78% of patients achieved an iPTH reduction of ≥30% and 65% achieved a reduction of ≥50% whilst in the cinacalcet group the figures were 50% and 36% of patients. Concerning side effects, 4 of 69 patients developed hypercalcaemia in the paricalcitol arm, while 27 of 59 patients developed hypocalcemia in the cinacalcet arm.

For further information

http://www.eraedta2011.org/press.html

Bettina Albers
albers@albersconcept.de
+49(0)174-2165629



'/>"/>
SOURCE European Renal Association European Dialysis and Transplant Association (RDA-EDT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MAP Pharmaceuticals to Present Data on LEVADEX® at the 15th Congress of the International Headache Society
2. Cubist Pharmaceuticals Applauds Congressman Gingrey for Introducing Legislation to Help Fight Superbug Infections
3. Neurocrine Biosciences Announces elagolix Scientific Presentations at the 11th World Congress on Endometriosis
4. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
5. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
6. U.S. Congressman Michael Capuano to Receive "Lou Gehrig Award" from ALS TDI During Gala Event this November
7. Medical Imaging and Radiation Therapy Personnel Certification Bill Introduced in Congress
8. Oregon Homecare Providers Support Congressional Bill to Repeal Misguided Medicare Bidding Program
9. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
10. 2011 Retail Clinician Education Congress to Offer Exclusive Accreditation and Networking Opportunities for Retail Healthcare Professionals
11. BioSpecifics Announces Positive XIAPEX® Data Presented at XVI Annual Federation of European Societies for Surgery of the Hand Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... -- Stock-Callers is currently reviewing the following Medical ... WMGI ), Varian Medical Systems Inc. (NYSE: ... and NuVasive Inc. (NASDAQ: NUVA ). These companies ... negative finish on Thursday, January 12 th , 2017, with ... of health care companies in the S&P 500 were down ...
(Date:1/13/2017)... Jan. 13, 2017 Wichita Laser Clinic ... laser treatments to Wichita, Kansas ... advanced treatments for skin rejuvenation, getting rid of unwanted ... and vascular lesions. "Since being in the ... Wichita for laser tattoo removal ...
(Date:1/13/2017)... Jan. 13, 2017  Secretary of Health Karen ... and community members at Misericordia University and discussed the ... Pennsylvania . "The opioid ... so far in my professional career," Secretary Murphy said. ... been hit hard by heroin and prescription opioid overdoses. ...
Breaking Medicine Technology:
(Date:1/14/2017)... ... January 13, 2017 , ... According to a December 9 ... may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. Southern ... wellness benefits linked to a Mediterranean diet are only some of the many ...
(Date:1/13/2017)... ... 2017 , ... A January 10 article in the Daily Star ... publication, with an emphasis on some new techniques that the publication says are becoming ... more casually to his patients and colleagues as Dr. J, comments that the best ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about ... they brush their teeth. Sadly, most dental hygiene products in the market contain chemical ... For these people, continuing their daily oral care routine to keep their teeth white ...
(Date:1/13/2017)... ... 2017 , ... The Joint Corp. was recently ranked in ... by entrepreneurs and franchisors as a top competitive measurement, the Franchise 500® ranked ... strength and stability, growth rate, and brand power. , “It is always an ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green ... if they can show their work is in the national interest. There are two ... having to be sponsored by an employer; and 2) the submission is made directly ...
Breaking Medicine News(10 mins):